Home/Pipeline/ADSC Therapy for Crohn's Fistula

ADSC Therapy for Crohn's Fistula

Perianal Fistulizing Crohn's Disease

Phase 1/2Inferred Development

Key Facts

Indication
Perianal Fistulizing Crohn's Disease
Phase
Phase 1/2
Status
Inferred Development
Company

About A4Cell

A4Cell is a pioneering regenerative medicine company leveraging adipose-derived stem cells (ADSCs) to develop novel therapies for unmet medical needs. Its core technology platform isolates and expands potent stem cells from fat tissue, offering a minimally invasive and abundant cell source. The company is advancing a pipeline of cell therapy candidates targeting conditions like osteoarthritis, Crohn's disease, and other inflammatory disorders. As a private, research-stage biotech, A4Cell is positioned to capitalize on the growing cell therapy market through strategic development and potential partnerships.

View full company profile

Other Perianal Fistulizing Crohn's Disease Drugs

DrugCompanyPhase
ExoFlo™Direct BiologicsPhase 1b/2a